IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses
SYDNEY, AUSTRALIA, Nov. 08, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announced positive data from its Phase I study of IMP761, its first-in-class LAG-3 agonist antibody, from a late-breaking abstract at ACR Convergence 2026 in Orlando, Florida. ACR Convergence is the annual scientific meeting of the American College of Rheumatology.
Covered in this story
Call it yourself
No calls on $ACR yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Acres Commercial Realty Corp →Dalsna Finance is currently tracking 5 stories mentioning Acres Commercial Realty Corp, the earliest published 7 Nov 2026.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.